Applicant, as named in the Orange Book

Merck Sharp Dohme

Next listed expiry: Prevymis on 30 Aug 2031. 4 products with live protection, 2 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Prevymis · 2 strengths letermovir	letermovir	209939	30 Aug 2031	exclusivity
Prevymis · 2 strengths letermovir	letermovir	209940	28 Feb 2033	patent
Belsomra · 4 strengths suvorexant	suvorexant	204569	29 May 2033	patent
Welireg belzutifan	belzutifan	215383	30 Jun 2042	patent

Recent events

25 Oct 2026Stromectol · Generic approved 9 Mar 2026
25 Oct 2026Stromectol · Generic approved 7 Apr 2026
25 Oct 2026Belsomra · Generic tentatively approved 22 Dec 2025
25 Oct 2026Noxafil · Generic approved 29 Jun 2026
25 Oct 2026Pepcid Preservative Free In Plastic Container · Generic approved 12 May 2026
25 Oct 2026Stromectol · Generic approved 26 Feb 2026
24 Oct 2026Welireg · Exclusivity expires within 90 days I-93114 Dec 2026

Products without listed protection (2)

Drug	Ingredient	NDA	Earliest generic entry	Basis
Stromectol ivermectin	ivermectin	050742	open now	no listed protection
Temodar temozolomide	temozolomide	022277	open now	no listed protection